Navigation Links
Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA
Date:11/24/2009

BEIJING, Nov. 24 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic China, today reported it will exhibit at the 62nd PHARMCHINA as a member of the Beijing pharmaceutical delegation.

Time: November 26-28, 2009

Venue: International Convention Center, Chengdu

The Beijing delegation features more than twenty pharmaceutical companies from Beijing, including Beijing Shuanghe Group, Beijing Pharmaceutical Group, and Tongrentang. As a member of the delegates, Lotus will continue to market its drugs that have established certain market share in China and introduce three potential new drugs that are subject to the State Food and Drug Administration's approval. These drugs include Laveo-Bambutero for asthma, Gliclazide-Controlled Release Tablets for type 2 diabetes and Isosorbide Mononitrate-Sustained Release Tablets for coronary artery disease.

About PHARMCHINA

PHARMCHINA is the largest and most recognized exhibition in the Chinese pharmaceutical industry over the last thirty years. With a gross floor area of more than 60,000 square meters and leading professional and academic forums, it attracts more than 1,900 exhibitors. PHARMCHINA is a diversified trading and exchange platform for pharmaceutical companies. For more information, please see http://www.pharmchina.com.cn .

About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. More than 8,000 products are sold by Liang Fang directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces.

    For more information, please contact:

    Lotus Pharmaceuticals, Inc.
     Yan ZENG, CFO
     Tel:   +86-10-6389-9868
     Email: zy@lotuspharma.com

SOURCE Lotus Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. Reports Third-Quarter 2009 Results
2. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
3. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
4. Bioniche Pharma and Academic Pharmaceuticals, Inc. Announce the Introduction of Sotalol Hydrochloride Injection
5. Brookstone Pharmaceuticals, LLC becomes Acella Pharmaceuticals, LLC
6. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
7. Biostar Pharmaceuticals, Inc. Announces Record Third Quarter 2009 Financial Results
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
10. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
11. BioMarin Acquires Huxley Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... --  Genomic Health, Inc. (Nasdaq: GHDX ) today reported ... December 31, 2015. --> --> ... with $69.1 million in the fourth quarter of 2014, an increase ... percent compared with the same period in the prior year. ... million in the fourth quarter of 2015, an increase of 9 ...
(Date:2/10/2016)... PITTSBURGH , 10 februari 2016 ... detta pressmeddelande får inte distribueras, vare sig ... inga anmälningssedlar kommer att accepteras från eller ... där Erbjudandet, distribution av detta pressmeddelande eller ... mot tillämpliga lagar eller regler eller skulle ...
(Date:2/10/2016)... 2016 Mylan N.V. (NASDAQ, TASE: MYL) today ... ended December 31, 2015. --> ... total revenues of $9.45 billion, up 28% on a ... revenues of $9.43 billion. Excluding the impact of the ... branded generics business (the "EPD Business"), full year adjusted ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... expand the ability of Medicare Advantage organizations to deliver medical services via telehealth, ... , “ATA has been advocating for such language for many years. Although ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... company offering education, research and medical media, has launched Contagion® , ... infectious diseases. , As the all-inclusive resource for infectious disease information, Contagion ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix announced on Wednesday ... , an emergency medicine professional association, to support the organization's newly established physician ... Academy of Emergency Medicine, or AAEM, seeks to empower emergency physicians to control ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Peyman Ghasri, ... now offering a variety of comprehensive procedures for facial enhancement. The treatments now ... restoration, lip enhancement and nasal reshaping. , As a result, patients can ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Gout is like ... brings pain that is often severe, with intense swelling and redness. It is triggered ... million people, but older adults are the most susceptible, according to the February 2016 ...
Breaking Medicine News(10 mins):